Shots:

• Winlevi is a first-in-class topical androgen receptor inhibitor approved by the US FDA for the treatment of acne in patients (age ≥12 yrs.) with a new mechanism of action (MOA) after ~ 40 yrs.
• Result: Winlevi demonstrated treatment success and reductions in acne lesions and was well tolerated when used q2w (in pivotal clinical trials). Additionally- the most frequently observed local skin reaction was mild erythema
• Winlevi (clascoterone cream 1%) is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris by limiting sebum production and inflammation. It is expected to be available in the US in early 2021

­ Ref: PR Newswire | Image: PR Newswire